{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.2","upperLimit":"14.0","value":"9.2"},{"comment":"The upper limit was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"9.3","upperLimit":"NA","value":"17.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from date of first study treatment to date of death from any cause. Patients last known to be alive were to be censored at the date of last contact. OS was analyzed and displayed graphically for each expansion cohort separately using the Kaplan-Meier method. The median event time and corresponding two-sided 95%CI were provided for each cohort. OS was first analyzed when the primary endpoint of CR was analyzed in the respective expansion cohort.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received SC or IV administration of azacitidine at the starting dose of 75 mg/m2/day for 7 days every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD.","id":"OG000","title":"AML Cohort"},{"description":"Participants received SC or IV administration of azacitidine at the starting dose of 75 mg/m2/day for 7 days every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD.","id":"OG001","title":"MDS Cohort"}],"paramType":"MEDIAN","populationDescription":"The full analysis population included all participants who received at least 1 dose of any study treatment.","reportingStatus":"POSTED","timeFrame":"maximum of approximately 32 months in AML cohort and 32 months in MDS cohort","title":"Kaplan-Meier Estimate of Median Overall Survival (OS) in the AML and MDS Cohorts","type":"SECONDARY","unitOfMeasure":"Months"}